Literature DB >> 36269328

A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model.

Nourhan H AbdelAllah1,2, Ahmed F Azmy1, Mohamed E Rashed3, Sameh AbdelGhani4,5, Yasser Gaber1,6.   

Abstract

Cholera and hepatitis A are serious infections spread by consuming contaminated food or water. Vaccination is the most effective strategy to prevent them. Inactivated vaccines are available for both diseases. Our goal in this study is to evaluate the immunogenic response of hepatitis A and cholera combination vaccines compared to the separate vaccines. Hepatitis A and cholera vaccine formulations with and without adjuvants (alum or chitosan) were developed and injected into mice intraperitoneally. We measured the rate of seroconversion; serum-specific antibody titers; lymphoproliferation analysis; cytokine secretions for IL2, IL4, IL10, and IFN-; and a challenge test against cholera strains in the vaccinated mice. Based on the results, the combined vaccination formulation, whether adjuvanted or not, significantly boosted the immune response on both humoral and cellular levels against both hepatitis A and cholera antigens compared to the individual vaccines. These findings validated an important concept for developing an effective combined cholera and hepatitis A vaccine that could be introduced as a novel combined vaccine for travelers as part of a standard immunization schedule. KEY POINTS: • Cholera and hepatitis A combined vaccines (with or without adjuvants) were prepared. • The vaccines were injected into mice groups for humoral and cellular immunity evaluation. • Combined vaccines gave substantial protection against both immunogens.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adjuvant; Cholera; Hepatitis A; Immune response; Vaccine

Year:  2022        PMID: 36269328     DOI: 10.1007/s00253-022-12222-4

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   5.560


  15 in total

1.  Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines.

Authors:  P A Czeschinski; N Binding; U Witting
Journal:  Vaccine       Date:  2000-01-06       Impact factor: 3.641

2.  The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.

Authors:  Chen Dong; Xing Dai; Ji-Hong Meng
Journal:  Vaccine       Date:  2006-11-13       Impact factor: 3.641

3.  Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years.

Authors:  David Overbosch; François Peyron; Nicole Picot; Jean-Paul Varichon; Rafaele Dumas; Laurent Chambonneau; Françoise Weber
Journal:  J Travel Med       Date:  2005 Nov-Dec       Impact factor: 8.490

Review 4.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

5.  Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine.

Authors:  H Kollaritsch; J U Que; C Kunz; G Wiedermann; C Herzog; S J Cryz
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

Review 6.  Immunomodulatory properties of chitosan polymers.

Authors:  Hannah B T Moran; Joanna L Turley; Mats Andersson; Ed C Lavelle
Journal:  Biomaterials       Date:  2018-08-30       Impact factor: 12.479

7.  Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.

Authors:  Lars Vibe Andreasen; Lasse Bøllehuus Hansen; Peter Andersen; Else Marie Agger; Jes Dietrich
Journal:  Vaccine       Date:  2015-02-17       Impact factor: 3.641

8.  Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin.

Authors:  Yan Gao; Qiudong Su; Yao Yi; Zhiyuan Jia; Hao Wang; Xuexin Lu; Feng Qiu; Shengli Bi
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 9.  Recent advances of vaccine adjuvants for infectious diseases.

Authors:  Sujin Lee; Minh Trang Nguyen
Journal:  Immune Netw       Date:  2015-04-23       Impact factor: 6.303

10.  Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.

Authors:  Asmaa Gohar; Nourtan F Abdeltawab; Nahla Shehata; Magdy A Amin
Journal:  Papillomavirus Res       Date:  2019-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.